News RSS Feed
Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia
Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology
Posted: June 2, 2014, 7:00 pm
Ibrutinib (IMBRUVICA®) RESONATE™ Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3 data (Abstract LBA7008) featured in the official press program of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine
Posted: June 2, 2014, 7:00 pm
IMAAGEN Data Demonstrate that Abiraterone Acetate Plus Prednisone (5mg once daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC)
Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical OncologyHORSHAM, PA, June 2, 2014 – Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use of abiraterone acetate plus prednisone (5 mg once daily) in patients with non-metastatic castration-resistant prostate cancer (M0-CRPC) at high risk of developing metastatic disease.
Posted: June 2, 2014, 2:30 pm
Legendary Coach Mike “Coach K” Krzyzewski Aims To Inspire Severe Joint Pain Sufferers To Seek Treatment So They Can Return To Helping Causes In Their Communities
Getting Back to Giving Back campaign celebrates and shares the inspirational stories of those who have had joint replacement and returned to helping causes that bring hope and relief to those in need
Posted: May 29, 2014, 8:45 pm
DePuy Synthes Joint Reconstruction Introduces New Advancements in Hip, Knee and Shoulder Replacement New solutions address clinical and economic needs
WARSAW, IN – (May 22, 2014) DePuy Synthes Joint Reconstruction*, a global leader in joint replacement solutions, announced today the introduction of three new products for hip, knee and shoulder replacement. These products are key examples of how the company is advancing patient care while also making surgical processes and procedures more efficient for surgeons and the health care system overall.
Posted: May 29, 2014, 4:00 pm
Care4Today™ Mobile Health Manager, a Free, Secure Digital Platform to Help Manage Medicines, Launches in the United Kingdom
Not taking medication correctly, or forgetting altogether, can have a significant impact on health, often resulting in delayed recovery or even hospitalisation6.
Posted: May 22, 2014, 10:15 pm
Johnson & Johnson Medical Devices & Diagnostics Businesses Expanding Market Leadership with Innovative Products and Customer-Focused Solutions
More than 30 major product filings planned through 2016Leading the industry in emerging market salesNew Brunswick, N.J.
Posted: May 22, 2014, 3:45 pm
Janssen Withdraws Application In European Union Seeking Approval Of Intravenously Administered Simponi®
LEIDEN, THE NETHERLANDS, May 19, 2014 – Janssen Biologics B.V.
Posted: May 21, 2014, 2:30 pm
Breakthrough technology redefines ultrasonic energy with HARMONIC® promise of precision, now combined with larger vessel sealingFirst purely ultrasonic device with a 7mm vessel sealing indication
Posted: May 19, 2014, 5:00 pm
OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection
Simeprevir provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe
Posted: May 16, 2014, 4:00 pm
Janssen Labs Expanding and Accelerating Coast to Coast -- Unveils Plan to Enhance the Innovation Ecosystem with New Incubator in South San Francisco and Awards One Year of Lab Space to Three Innovative Healthcare Companies in Boston
San Diego, CA, May 14, 2014 — Janssen Labs, part of Janssen Research & Development, LLC (Janssen), today announced plans to open Janssen Labs @South San Francisco, a new 30,000-square foot, standalone operation based at 329 Oyster Point Boulevard, South San Francisco, CA. The new location will accommodate up to 50 independent, emerging companies to be co-located with staff from Johnson & Johnson Innovation, LLC.
Posted: May 14, 2014, 3:00 pm
Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Submitted to the U.S. FDA for the Treatment of Schizoaffective Disorde
New submission based on positive data from a 15-month schizoaffective relapse prevention study
Posted: May 13, 2014, 6:45 pm
Janssen Announces Expanded Collaboration with International Partnership for Microbicides for Development and Commercialization of Dapivirine for Prevention of Sexual Transmission of HIV
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide
Posted: May 8, 2014, 4:30 pm
Janssen Submits Supplemental New Drug Application to U.S. FDA for OLYSIO™ (Simeprevir) for Once-Daily Use in Combination with Sofosbuvir for 12 Weeks for the Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
Filing Includes Data from Treatment-Naïve Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis
Posted: May 7, 2014, 5:45 pm
Study Found INVEGA® SUSTENNA® (paliperidone palmitate) Once-Monthly Long-Acting Therapy Delayed Time to and Reduced Risk of Relapse in Individuals with Schizoaffective Disorder as Monotherapy and Adjunctive Therapy
Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning
Posted: May 6, 2014, 10:30 pm
Landmark Study Shows Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Significantly Delayed Time to Relapse in Patients with Schizophrenia Compared to Daily Oral Antipsychotic
First prospective, randomized clinical trial to reflect context of “real world” issues in treating schizophrenia, including recent incarceration and substance abuse
Posted: May 5, 2014, 3:45 pm
Future Care Scholarships Help Support Students Pursuing Careers in Healthcare IndustryFt. Washington, PA, May 1, 2014 – McNeil Consumer Healthcare Division of McNEIL-PPC, Inc., the makers of TYLENOL®, announces the 24th annual TYLENOL® Future Care Scholarship, and is now accepting applications through June 30, 2014.
Posted: May 1, 2014, 8:15 pm
Johnson & Johnson Announces New Collaboration with Stop TB Partnership’s Global Drug Facility to Enhance Access to Anti-TB Compound
New Brunswick, NJ – April 29, 2014 – Johnson & Johnson today announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF), to facilitate access to the Company’s anti-tuberculosis medicine. This public-private partnership was established by the newly formed Janssen Global Public Health and is the latest in the Company’s overall efforts to improve public health.
Posted: April 29, 2014, 2:30 pm
Johnson & Johnson and American College of Sports Medicine Form Global Alliance to Advance Human Health and Performance
Proven Principles in Sport Science and Energy Management Shed New Light on Improving Health OutcomesNew York, NY (April 29, 2014) –Johnson & Johnson announced today, in partnership with the American College of Sports Medicine (ACSM), the creation of the Global Alliance for Health and Performance (the Global Alliance). The Global Alliance will work to educate and promote the ways in which proven principles of sport science and energy management can move society from a disease state to a performance state.
Posted: April 29, 2014, 11:00 am
VOKANAMET® (canagliflozin and immediate release metformin hydrochloride fixed dose combination) approved in the European Union for treatment of adults with type 2 diabetes 
BEERSE, April 25 2014 – Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control. Canagliflozin as a single agent was approved as INVOKANA® in the European Union in November 2013.
Posted: April 25, 2014, 5:45 pm
New Brunswick, NJ (April 24, 2014) – Johnson & Johnson today announced that its Board of Directors has declared a 6.1% increase in the quarterly dividend rate, from $0.66 per share to $0.70 per share. The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, NJ.“In recognition of our 2013 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the dividend for the 52nd consecutive year,” said Alex Gorsky, Chairman and Chief Executive Officer of the Company.
Posted: April 24, 2014, 4:45 pm
First treatment approved for patients with rare blood disorder
Posted: April 24, 2014, 3:00 pm
New Brunswick, NJ (April 23, 2014) – Johnson & Johnson (NYSE: JNJ) will host a review of its Medical Devices & Diagnostics business for the investment community beginning at 9:30 a.m. (Eastern Time) on Thursday, May 22, 2014 at the Hyatt Regency Hotel in New Brunswick, New Jersey and ending at approximately 2:30 p.m.Dominic J. Caruso, Vice President, Finance and Chief Financial Officer will host the meeting which will feature presentations by Johnson & Johnson’s senior management within the Medical Devices and Diagnostics organization.
Posted: April 23, 2014, 8:45 pm
The Makers Of PEPCID® Partner With Ted Allen And Eater.Com To Celebrate Great Taste Without The Heartburn Pain
FORT WASHINGTON, PA (April 16, 2014) – To help food enthusiasts in their pursuit of elevated tastes, the makers of PEPCID® are teaming with culinary expert Ted Allen and Eater.com to launch the PEPCID® Tastemakers Series. Heartburn doesn’t just affect those chowing down on massive plates of hot wings or indulging in fried food at the ballpark. Heartburn can strike anywhere, even after a decadent meal at a Michelin-starred restaurant.
Posted: April 16, 2014, 5:15 pm
Sales of $18.1 Billion increased 3.5% Versus 2013 First Quarter;First-Quarter EPS was $1.64Excluding Special Items, 2014 First-Quarter EPS of $1.54 increased 6.9%*
Posted: April 15, 2014, 1:30 pm
Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)
Additional Studies Presented in Genotype 1 and Genotype 4 Hepatitis C Patient Subgroups Underscore Benefit of Simeprevir-based Treatment Regimens
Posted: April 14, 2014, 2:45 pm
New submission based on positive Phase 3 data from the RESONATE™ trial
Posted: April 8, 2014, 4:00 pm
Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C
OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin
Posted: April 2, 2014, 2:00 pm
Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy
RARITAN, NJ, April 1, 2014– Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir, a protease inhibitor developed by Janssen R&D Ireland and marketed as PREZISTA® in the U.S., with cobicistat, an investigational pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc.
Posted: April 1, 2014, 2:45 pm
Bethesda, MD (April 1, 2014) – Johnson & Johnson announced it has entered a multi-year agreement to be the Official Healthcare Partner of the USO. The announcement was made today during a ceremony to mark the opening of the USO’s Warrior and Family Center at Bethesda, located on the campus of Naval Support Activity Bethesda, home of Walter Reed National Military Medical Center.
Posted: March 31, 2014, 10:30 pm
Janssen Expands the EXPLORER Global Cardiovascular Research Program with Three New Studies Evaluating XARELTO® in Patients at Risk for Venous Thromboembolism
Raritan, NJ (March 31, 2014) — Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO® (rivaroxaban), the most studied and broadly indicated oral Factor Xa inhibitor in the world today. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient populations, including those at risk for DVT or PE due to a concurrent medical illness.
Posted: March 31, 2014, 3:45 pm
Johnson & Johnson Announces Acceptance Of Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics
New Brunswick, NJ, March 31, 2014 -- Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. This acceptance was made after consultation with the relevant works councils and trade unions. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions.
Posted: March 31, 2014, 2:15 pm
Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy In Treatment Of Moderate To Severe Plaque Psoriasis
Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab
Posted: March 24, 2014, 4:45 pm
Siltuximab Receives CHMP Positive Opinion for use in the Treatment of Multicentric Castleman’s Disease, a very Rare Blood Disorder
Beerse / Belgium, March 21, 2014 – Janssen-Cilag International NV (“Janssen”) announced today that The Committee for Medical Products for Human Use (CHMP) of The European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a marketing authorisation for siltuximab for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative.1 If approved, siltuximab would be the first medicine to receive regulatory approval in the EU for treatment of MCD patients.
Posted: March 21, 2014, 9:45 pm
Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment EfficacyTitusville, NJ – (March 20, 2014) - Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of paliperidone palmitate 3-month formulation, an investigational treatment for symptoms of schizophrenia in adults.
Posted: March 20, 2014, 1:30 pm
New Depuy Synthes Advantage™ Provides Solutions Focused On Improving Clinical And Economic Outcomes And Patient Satisfaction
Solutions include MedTrak, Inc.’s CareSense System To Track and Analyze Patient Outcomes, Patient Satisfaction and Cost RAYNHAM, MA – (March 13, 2014) – Today DePuy Synthes Companies of Johnson & Johnson introduced DePuy Synthes Advantage™, a unique suite of provider-focused solutions focused on complementing the company’s extensive portfolio of clinically proven products with solutions that assist in driving optimal clinical and economic outcomes while striving to improve the patient experience.
Posted: March 13, 2014, 6:00 pm
WARSAW, IN – (March 12, 2014) – DePuy Synthes Joint Reconstruction*, a global leader in joint replacement, today announced the introduction of two new technologies for the ATTUNE® Knee System—the ATTUNE Rotating Platform Knee and the Anatomic Patella. The announcement was made in conjunction with the 2014 American Academy of Orthopaedic Surgeons Meeting (AAOS) in New Orleans.
Posted: March 12, 2014, 7:30 pm
New Brunswick, NJ (March 11, 2014) - Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15th, to review first-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer and Louise Mehrotra, Vice President, Investor Relations, will host the call.Investors and other interested parties may access the conference call in the following ways:
Posted: March 11, 2014, 10:30 pm
New form provides a convenient solution for powerful allergy reliefFORT WASHINGTON, PA (March 5, 2014) – The makers of ZYRTEC® are pleased to announce the launch of a new form to the ZYRTEC® portfolio of allergy-relief products – a convenient oral, dissolvable tablet. Delivering the same effective 24-hour relief, ZYRTEC® Dissolve Tabs are now available for adults and children, age 6 years and above, and can be purchased at all major retailers and pharmacies.
Posted: March 8, 2014, 12:00 am